Literature DB >> 22721817

Extended drug delivery by contact lenses for glaucoma therapy.

Cheng-Chun Peng1, Michael T Burke, Blanca E Carbia, Caryn Plummer, Anuj Chauhan.   

Abstract

We combine laboratory-based timolol release studies and in vivo pharmacodynamics studies in beagle dogs to evaluate the efficacy of glaucoma therapy through extended wear contact lenses. Commercial contact lenses cannot provide extended delivery of ophthalmic drugs and so the studies here focused on increasing the release duration of timolol from ACUVUE TruEye contact lenses by incorporating vitamin E diffusion barriers. The efficacy of timolol delivered via extended wear contact lenses was then compared to eye drops in beagle dogs that suffer from spontaneous glaucoma. The lenses were either replaced every 24h or continuously worn for 4 days, and the pharmacodynamics effect of changes in the intraocular pressure (IOP) of timolol from the ACUVUE TruEye contact lenses can be significantly increased by incorporation of vitamin E. The in vivo studies showed that IOP reduction from baseline by pure contact lens on daily basis was comparable with that by eye drops but with only 20% of drug dose, which suggested higher drug bioavailability for contact lenses. In addition, by inclusion of vitamin E into the lenses, the IOP was reduced significantly during the 4-day treatment with continuous wear of lens.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22721817     DOI: 10.1016/j.jconrel.2012.06.017

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  26 in total

1.  Extended release of ketotifen from silica shell nanoparticle-laden hydrogel contact lenses: in vitro and in vivo evaluation.

Authors:  Furqan A Maulvi; Mayurkumar A Mangukiya; Prachi A Patel; Rutvi J Vaidya; Akshay R Koli; Ketan M Ranch; Dinesh O Shah
Journal:  J Mater Sci Mater Med       Date:  2016-05-13       Impact factor: 3.896

2.  Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device.

Authors:  Karen E Samy; Yiqi Cao; Jean Kim; Nina Rosa Konichi da Silva; Audrey Phone; Michele M Bloomer; Robert B Bhisitkul; Tejal A Desai
Journal:  J Ocul Pharmacol Ther       Date:  2019-01-07       Impact factor: 2.671

Review 3.  Nanoparticles for drug delivery to the anterior segment of the eye.

Authors:  Dileep R Janagam; Linfeng Wu; Tao L Lowe
Journal:  Adv Drug Deliv Rev       Date:  2017-04-06       Impact factor: 15.470

4.  Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery.

Authors:  Michael G Lancina; Sudha Singh; Uday B Kompella; Shahid Husain; Hu Yang
Journal:  ACS Biomater Sci Eng       Date:  2017-06-09

5.  Development of an In Vitro Ocular Platform to Test Contact Lenses.

Authors:  Chau-Minh Phan; Hendrik Walther; Huayi Gao; Jordan Rossy; Lakshman N Subbaraman; Lyndon Jones
Journal:  J Vis Exp       Date:  2016-04-06       Impact factor: 1.355

6.  Ophthalmic delivery of hydrophilic drugs through drug-loaded oleogels.

Authors:  Russell Macoon; Anuj Chauhan
Journal:  Eur J Pharm Sci       Date:  2020-11-01       Impact factor: 4.384

7.  In vivo drug delivery via contact lenses: The current state of the field from origins to present.

Authors:  Liana D Wuchte; Stephen A DiPasquale; Mark E Byrne
Journal:  J Drug Deliv Sci Technol       Date:  2021-02-18       Impact factor: 5.062

8.  A biodegradable ocular implant for long-term suppression of intraocular pressure.

Authors:  Xu Wen Ng; Kerh Lin Liu; Amutha Barathi Veluchamy; Nyein Chan Lwin; Tina T Wong; Subbu S Venkatraman
Journal:  Drug Deliv Transl Res       Date:  2015-10       Impact factor: 4.617

Review 9.  Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.

Authors:  Uday B Kompella; Rachel R Hartman; Madhoosudan A Patil
Journal:  Prog Retin Eye Res       Date:  2020-09-04       Impact factor: 21.198

Review 10.  Nanotechnology approaches for ocular drug delivery.

Authors:  Qingguo Xu; Siva P Kambhampati; Rangaramanujam M Kannan
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.